ReviewPathologie (Heidelberg, Germany)2025
[Molecular pathology in non-small-cell lung cancer: current and emerging biomarkers].
Review in Pathologie (Heidelberg, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Erratum issued
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In the classification of lung cancer, the basic division into small cell and non-small cell carcinomas continues to apply. Despite the same histological subtyping, it is known that there are defined genetic changes in the tumor cells that significantly determine tumor growth as "drivers", so that their blockade can significantly influence the clinical course. Thus, in the last 10 years, the treatment of lung cancer has been increasingly supplemented by the establishment of tumor-specific targeted drugs and immunomodulatory approaches. This development has led to increasingly differentiated and individualized approaches to treatment. Pathology and especially molecular pathological diagnostics play a central role here, as an increasing number of biomarkers must be examined.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.